(CercleFinance.com) – Moderna and Carisma Therapeutics, specialists in macrophage-based therapies, announced yesterday the conclusion of a strategic collaboration to develop and commercialize in vivo monocyte therapies with modified chimeric antigen receptor (CAR-M) for cancer treatment.
“In vivo delivery directly to monocytes and macrophages enables a standard therapeutic approach that uses patients’ own cells to deliver a truly personalized treatment,” says Steven Kelly, President and CEO of Carisma.
The aim is to develop a new therapeutic approach for the treatment of cancer by combining Carisma’s expertise in macrophage biology, and Moderna’s pioneering in vivo mRNA delivery technologies.
Under the terms of the deal, Carisma will receive an initial cash payment of $ 45 million and an investment from Moderna in the form of a convertible bond of $ 35 million.
Carisma will be responsible for the discovery and optimization of development candidates while Moderna will lead the clinical development and commercialization of therapeutic products resulting from the agreement.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
